tiprankstipranks
Esperion Therapeutics (DE:0ET)
NASDAQ:0ET
Germany Market
0ET
Esperion
RESEARCH TOOLSreports

Esperion (0ET) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0ET Analyst Ratings

Hold
6Ratings
Hold
0 Buy
5 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Esperion
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0ET Stock 12 Month Forecast

Average Price Target

€2.52
▲(46.51% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Esperion in the last 3 months. The average price target is €2.52 with a high forecast of €2.84 and a low forecast of €1.54. The average price target represents a 46.51% change from the last price of €1.72.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","-1":"-€1","0.25":"€0.25","1.5":"€1.5","2.75":"€2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.842349272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5199852691999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.542494422,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.54</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.652,2.666642251692308,2.6812845033846155,2.6959267550769233,2.710569006769231,2.7252112584615387,2.7398535101538464,2.7544957618461536,2.7691380135384613,2.783780265230769,2.7984225169230768,2.8130647686153845,2.827707020307692,{"y":2.842349272,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.652,2.6418450207076924,2.6316900414153848,2.621535062123077,2.6113800828307694,2.6012251035384617,2.591070124246154,2.580915144953846,2.570760165661538,2.5606051863692305,2.550450207076923,2.540295227784615,2.5301402484923075,{"y":2.5199852691999998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.652,2.5666534170769233,2.4813068341538465,2.395960251230769,2.3106136683076923,2.2252670853846155,2.1399205024615386,2.054573919538462,1.9692273366153847,1.8838807536923077,1.7985341707692308,1.713187587846154,1.6278410049230772,{"y":1.542494422,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.692,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.783,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.176,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.198,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.411,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.346,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.757,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.333,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.582,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.652,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€2.84Average Price Target€2.52Lowest Price Target€1.54
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on DE:0ET
Serge Belanger
Needham
Needham
―
Hold
―
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Passage Bio (PASG), Esperion (ESPR)
H.C. Wainwright Analyst forecast on DE:0ET
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€2.74
Hold
59.21%
Upside
Downgraded
05/04/26
Esperion downgraded to Neutral from Buy at H.C. WainwrightEsperion downgraded to Neutral from Buy at H.C. Wainwright
Jefferies Analyst forecast on DE:0ET
Dennis Ding
Jefferies
Jefferies
€2.84
Hold
65.25%
Upside
Downgraded
05/04/26
Esperion downgraded to Hold from Buy at JefferiesEsperion downgraded to Hold from Buy at Jefferies
Piper Sandler Analyst forecast on DE:0ET
David Amsellem
Piper Sandler
Piper Sandler
€7.8→€2.74
Hold
59.21%
Upside
Downgraded
05/01/26
Esperion downgraded to Neutral from Overweight at Piper SandlerEsperion downgraded to Neutral from Overweight at Piper Sandler
Cantor Fitzgerald Analyst forecast on DE:0ET
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€2.74
Hold
59.21%
Upside
Downgraded
05/01/26
Esperion downgraded to Neutral from Overweight at Cantor FitzgeraldEsperion downgraded to Neutral from Overweight at Cantor Fitzgerald
Bank of America Securities Analyst forecast on DE:0ET
Jason Zemansky
Bank of America Securities
Bank of America Securities
€1.54
Sell
-10.32%
Downside
Reiterated
03/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Passage Bio (NASDAQ: PASG), Phreesia (NYSE: PHR) and Esperion (NASDAQ: ESPR)
Goldman Sachs Analyst forecast on DE:0ET
Paul Choi
Goldman Sachs
Goldman Sachs
€2.6
Hold
51.15%
Upside
Reiterated
03/03/26
Balanced Risk-Reward Keeps Esperion at Hold Amid Complex Corstasis Acquisition and CHF Market Challenges
Citizens JMP Analyst forecast on DE:0ET
Jason Butler
Citizens JMP
Citizens JMP
€3.47
Buy
101.53%
Upside
Reiterated
09/22/25
Citizens JMP Sticks to Its Buy Rating for Esperion (ESPR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on DE:0ET
Serge Belanger
Needham
Needham
―
Hold
―
Reiterated
05/12/26
Analysts' Top Healthcare Picks: Passage Bio (PASG), Esperion (ESPR)
H.C. Wainwright Analyst forecast on DE:0ET
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
€2.74
Hold
59.21%
Upside
Downgraded
05/04/26
Esperion downgraded to Neutral from Buy at H.C. WainwrightEsperion downgraded to Neutral from Buy at H.C. Wainwright
Jefferies Analyst forecast on DE:0ET
Dennis Ding
Jefferies
Jefferies
€2.84
Hold
65.25%
Upside
Downgraded
05/04/26
Esperion downgraded to Hold from Buy at JefferiesEsperion downgraded to Hold from Buy at Jefferies
Piper Sandler Analyst forecast on DE:0ET
David Amsellem
Piper Sandler
Piper Sandler
€7.8→€2.74
Hold
59.21%
Upside
Downgraded
05/01/26
Esperion downgraded to Neutral from Overweight at Piper SandlerEsperion downgraded to Neutral from Overweight at Piper Sandler
Cantor Fitzgerald Analyst forecast on DE:0ET
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€2.74
Hold
59.21%
Upside
Downgraded
05/01/26
Esperion downgraded to Neutral from Overweight at Cantor FitzgeraldEsperion downgraded to Neutral from Overweight at Cantor Fitzgerald
Bank of America Securities Analyst forecast on DE:0ET
Jason Zemansky
Bank of America Securities
Bank of America Securities
€1.54
Sell
-10.32%
Downside
Reiterated
03/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Passage Bio (NASDAQ: PASG), Phreesia (NYSE: PHR) and Esperion (NASDAQ: ESPR)
Goldman Sachs Analyst forecast on DE:0ET
Paul Choi
Goldman Sachs
Goldman Sachs
€2.6
Hold
51.15%
Upside
Reiterated
03/03/26
Balanced Risk-Reward Keeps Esperion at Hold Amid Complex Corstasis Acquisition and CHF Market Challenges
Citizens JMP Analyst forecast on DE:0ET
Jason Butler
Citizens JMP
Citizens JMP
€3.47
Buy
101.53%
Upside
Reiterated
09/22/25
Citizens JMP Sticks to Its Buy Rating for Esperion (ESPR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Esperion

3 Months
Jason ButlerCitizens JMP
Success Rate
8/22 ratings generated profit
36%
Average Return
-4.32%
Copying Jason Butler's trades and holding each position for 3 Months would result in 36.36% of your transactions generating a profit, with an average return of -4.32% per trade.
1 Year
Jason ButlerCitizens JMP
Success Rate
10/22 ratings generated profit
45%
Average Return
-5.72%
Copying Jason Butler's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -5.72% per trade.
2 Years
Jason ButlerCitizens JMP
Success Rate
12/22 ratings generated profit
55%
Average Return
+6.68%
Copying Jason Butler's trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +6.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0ET Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
6
16
14
13
2
Buy
1
1
0
0
0
Hold
0
1
1
7
6
Sell
1
4
4
3
0
Strong Sell
1
1
0
0
0
total
9
23
19
23
8
In the current month, 0ET has received 2 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 0ET average Analyst price target in the past 3 months is 2.52.
Each month's total comprises the sum of three months' worth of ratings.

0ET Financial Forecast

0ET Earnings Forecast

Next quarter’s earnings estimate for 0ET is >-€0.01 with a range of -€0.06 to €0.05. The previous quarter’s EPS was -€0.09. 0ET beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0ET has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0ET is >-€0.01 with a range of -€0.06 to €0.05. The previous quarter’s EPS was -€0.09. 0ET beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0ET has Performed in-line its overall industry.

0ET Sales Forecast

Next quarter’s sales forecast for 0ET is €80.14M with a range of €66.38M to €89.09M. The previous quarter’s sales results were €69.42M. 0ET beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0ET has Performed in-line its overall industry.
Next quarter’s sales forecast for 0ET is €80.14M with a range of €66.38M to €89.09M. The previous quarter’s sales results were €69.42M. 0ET beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0ET has Performed in-line its overall industry.

0ET Stock Forecast FAQ

What is DE:0ET’s average 12-month price target, according to analysts?
Based on analyst ratings, Esperion Therapeutics’s 12-month average price target is 2.52.
    What is DE:0ET’s upside potential, based on the analysts’ average price target?
    Esperion Therapeutics has 46.51% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Esperion Therapeutics a Buy, Sell or Hold?
          Esperion Therapeutics has a consensus rating of Hold, which is based on 0 buy ratings, 5 hold ratings and 1 sell ratings.
            What is Esperion Therapeutics’s share price target?
            The average share price target for Esperion Therapeutics is 2.52. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €2.84 ,and the lowest forecast is €1.54. The average share price target represents 46.51% Increase from the current price of €1.72.
              What do analysts say about Esperion Therapeutics?
              Esperion Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Esperion Therapeutics?
                To buy shares of DE:0ET, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.